Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2539449 | 0.72 | MAPT (0.48) | XDHMAPTADORA3ADORA2BACHE | |
| SCHEMBL1150739 | 0.69 | XDH (0.47) | XDHMAPTADORA3ADORA2BACHE | |
| SCHEMBL380136 | 0.68 | MAPT (0.48) | XDHMAPTADORA3ADORA2BACHE | |
| SCHEMBL6233162 | 0.67 | XDH (0.51) | XDHMAPTADORA2BALDH1A1MAPK1 | |
| SCHEMBL28232233 | 0.66 | MAPT (0.42) | XDHMAPTADORA2BACHEGDA | |
| SCHEMBL3118423 | 0.66 | XDH (0.54) | XDHMAPTADORA2BHCAR2 | |
| SCHEMBL10997 | 0.65 | MAPT (0.53) | XDHMAPTADORA3ADORA2BACHE | |
| SCHEMBL932949 | 0.65 | MAPT (0.53) | XDHMAPTADORA2BACHEGDA | |
| SCHEMBL11661802 | 0.65 | XDH (0.56) | XDHMAPTHCAR2 | |
| SCHEMBL4128821 | 0.64 | XDH (0.56) | XDHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4288433-A | THIOETHER AND A XANTHINE DERIVATIVE | L'OREAL (FR) | 1981-09-08 | — | — | US | claimed |
| EP-1497444-B1 | METHODS FOR INCREASING POLYPEPTIDE PRODUCTION | IMMUNEX CORP (US) | 2015-11-04 | — | — | EP | disclosed |
| US-7452695-B2 | Methods for increasing polypeptide production | IMMUNEX CORPORATION (US) | 2008-11-18 | — | — | US | disclosed |
| US-20050233415-A1 | From mammal cells transformed with cytomegalovirus vector using xanthine derivatives (caffeine and/or theobromine) and/or hexamethylene bisacetamide; serum-free | IMMUNEX CORPORATION (US) | 2005-10-20 | — | — | US | disclosed |
| US-6872549-B2 | Methods for increasing polypeptide production | IMMUNEX CORPORATION (US) | 2005-03-29 | — | — | US | disclosed |
| US-20030211579-A1 | Methods for increasing polypeptide production | IMMUNEX CORPORATION | 2003-11-13 | — | — | US | disclosed |
| US-4288433-A | THIOETHER AND A XANTHINE DERIVATIVE | L'OREAL (FR) | 1981-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030211579-A1 | Methods for increasing polypeptide production | IAPP, NPEPPS, ANPEP | XDH 115/4885MAPT 2943/4885ADORA3 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.